Aktuellt
SENASTE
We lift our 2022-24 sales estimates by 4% post Q2, yet another quarter with a recovery in sales (13% y-o-y organic growth). However, Q2 also saw a continued small negative EBITDA as a result of increased growth investments. Bactiguard’s underlying BIP segment, its deeper penetration in current licence deals and its potential new deals within additional product categories present growth opportunities for the company.
LÄS MER
